The following is a summary of “Does autonomous macrophage-driven inflammation promote alveolar damage in COVID-19?” published in the December 2022 issue of Respiratory by Dockrell et al.

It is projected that the severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus will cause approximately 6.4 million fatalities and more than 550 million illnesses by the time July 2022 rolls around [1]. The continuous evolution of SARS-CoV-2 as it persistently spreads through the human population, as evidenced by the reduced activity of vaccines and monoclonals against Omicron BA.4 or BA.5 sub-variants [2], will have reverberating effects on society and the economy for number of years to come. 

These effects will continue to impact society and the economy for a number of years to come. For a good number of years into the future, these repercussions will continue to affect both society and the economy. Both the economy and society will continue to be impacted for a considerable amount of time into the foreseeable future as a direct result of these ramifications. As long as the virus remains capable of spreading to new locations, these effects are going to be in effect. 

As a direct result of this, it is absolutely essential to have a more comprehensive understanding of the pathophysiology of the disease and to devise treatment choices that are better tailored to the specific needs of the particular patient.